{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T20:38:42Z","timestamp":1795207122899,"version":"4.10.3"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T00:00:00Z","timestamp":1774828800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T00:00:00Z","timestamp":1774828800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Quemliclustat potently inhibits CD73, a key enzyme producing immunosuppressive adenosine. In a phase 1b trial (ARC-8), we evaluated safety and efficacy of quemliclustat combined with gemcitabine\/nab-paclitaxel (G\/nP) with or without zimberelimab (anti-programmed cell death protein 1 (PD-1)) in first-line metastatic pancreatic ductal adenocarcinoma (PDAC). During the dose-escalation phase, 22 patients were enrolled across five dose levels of quemliclustat (25\u2009mg, 50\u2009mg, 75\u2009mg, 100\u2009mg or 125\u2009mg) with G\/nP\u2009+\u2009zimberelimab. During the dose-expansion phase, 116 patients were enrolled, beginning with a single-arm, non-randomized cohort receiving quemliclustat 100\u2009mg\u2009+\u2009G\/nP\u2009+\u2009zimberelimab, followed by a randomized cohort in which patients were assigned in a 2:1 ratio to receive quemliclustat 100\u2009mg\u2009+\u2009G\/nP with or without zimberelimab. The primary endpoint was safety and tolerability; secondary endpoints included assessments of clinical activity and survival. In all treatment arms, the safety profile was consistent with that of G\/nP. Clinical response rates and survival outcomes were encouraging.\n                    <jats:italic>NR4A<\/jats:italic>\n                    family gene expression was upregulated by adenosine in vitro and by chemotherapy in human PDACs. High tumor\n                    <jats:italic>NR4A<\/jats:italic>\n                    expression was associated with improved overall survival (OS) in ARC-8 but not in two external cohorts from the PRINCE (G\/nP\u2009+\u2009nivolumab (nivo)) or Morpheus-PDAC (G\/nP) trials. Spatial tissue analyses revealed a scarcity of activated T cells near regions with high\n                    <jats:italic>NR4A1<\/jats:italic>\n                    expression, consistent with an immunosuppressed tumor microenvironment. In paired pretreatment\/posttreatment biopsies, maximal downregulation of\n                    <jats:italic>NR4A<\/jats:italic>\n                    expression was associated with T cell activation and improved OS, pointing to a biological link between tumor adenosine and clinical benefit. ClinicalTrials.gov identifier:\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/clinicaltrials.gov\/study\/NCT04104672\" ext-link-type=\"uri\">NCT04104672<\/jats:ext-link>\n                    .\n                  <\/jats:p>","DOI":"10.1038\/s41591-026-04283-z","type":"journal-article","created":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T09:03:05Z","timestamp":1774861385000},"page":"1267-1277","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Quemliclustat and chemotherapy with or without zimberelimab in metastatic pancreatic adenocarcinoma: a randomized phase 1 trial"],"prefix":"10.1038","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7142-1246","authenticated-orcid":false,"given":"Zev A.","family":"Wainberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-7459-6036","authenticated-orcid":false,"given":"Gulam A.","family":"Manji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Bahary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7234-2283","authenticated-orcid":false,"given":"Susanna V.","family":"Ulahannan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9281-480X","authenticated-orcid":false,"given":"Shubham","family":"Pant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R.","family":"Spigel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3449-1680","authenticated-orcid":false,"given":"Nataliya V.","family":"Uboha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5918-6004","authenticated-orcid":false,"given":"Paul E.","family":"Oberstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8024-9401","authenticated-orcid":false,"given":"Anwaar","family":"Saeed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon","family":"Beagle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji Yun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4128-5861","authenticated-orcid":false,"given":"Ben","family":"Weeder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shravani","family":"Shitole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karim","family":"Mrouj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer R.","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa G.","family":"Ensign","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2610-353X","authenticated-orcid":false,"given":"Daniel M.","family":"DiRenzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Walters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilson","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Kaplan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soonweng","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6671-5899","authenticated-orcid":false,"given":"Omar","family":"Kabbarah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8076-9199","authenticated-orcid":false,"given":"Eileen M.","family":"O\u2019Reilly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,30]]},"reference":[{"key":"4283_CR1","first-page":"12","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel, R. L., Giaquinto, A. N. & Jemal, A. Cancer statistics, 2024. CA Cancer J. Clin. 74, 12\u201349 (2024).","journal-title":"CA Cancer J. Clin."},{"key":"4283_CR2","doi-asserted-by":"publisher","first-page":"5510","DOI":"10.3390\/cancers13215510","volume":"13","author":"EM Anderson","year":"2021","unstructured":"Anderson, E. M., Thomassian, S., Gong, J., Hendifar, A. & Osipov, A. Advances in pancreatic ductal adenocarcinoma treatment. Cancers (Basel) 13, 5510 (2021).","journal-title":"Cancers (Basel)"},{"key":"4283_CR3","doi-asserted-by":"publisher","first-page":"3489","DOI":"10.18632\/oncotarget.27727","volume":"11","author":"ES Katayama","year":"2020","unstructured":"Katayama, E. S. et al. A comprehensive analysis of clinical trials in pancreatic cancer: what is coming down the pike? Oncotarget 11, 3489\u20133501 (2020).","journal-title":"Oncotarget"},{"key":"4283_CR4","doi-asserted-by":"publisher","first-page":"4504","DOI":"10.3390\/ijms20184504","volume":"20","author":"S Zeng","year":"2019","unstructured":"Zeng, S. et al. Chemoresistance in pancreatic cancer. Int. J. Mol. Sci. 20, 4504 (2019).","journal-title":"Int. J. Mol. Sci."},{"key":"4283_CR5","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1001\/jama.2021.13027","volume":"326","author":"W Park","year":"2021","unstructured":"Park, W., Chawla, A. & O\u2019Reilly, E. M. Pancreatic cancer: a review. JAMA 326, 851\u2013862 (2021).","journal-title":"JAMA"},{"key":"4283_CR6","doi-asserted-by":"publisher","first-page":"4136","DOI":"10.1200\/JCO.2023.41.16_suppl.4136","volume":"41","author":"AL Coveler","year":"2023","unstructured":"Coveler, A. L. et al. Safety and clinical activity of oleclumab (O) \u00b1 durvalumab (D) + chemotherapy (CT) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC): a phase 1b\/2 randomized study. J. Clin. Oncol. 41, 4136 (2023).","journal-title":"J. Clin. Oncol."},{"key":"4283_CR7","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1016\/S0140-6736(23)01366-1","volume":"402","author":"ZA Wainberg","year":"2023","unstructured":"Wainberg, Z. A. et al. NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial. Lancet 402, 1272\u20131281 (2023).","journal-title":"Lancet"},{"key":"4283_CR8","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/j.annonc.2021.01.070","volume":"32","author":"M Tempero","year":"2021","unstructured":"Tempero, M. et al. Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancreatic adenocarcinoma: phase III RESOLVE study. Ann. Oncol. 32, 600\u2013608 (2021).","journal-title":"Ann. Oncol."},{"key":"4283_CR9","doi-asserted-by":"publisher","first-page":"3185","DOI":"10.1200\/JCO.20.00590","volume":"38","author":"E Van Cutsem","year":"2020","unstructured":"Van Cutsem, E. et al. Randomized phase III trial of pegvorhyaluronidase alfa with nab-paclitaxel plus gemcitabine for patients with hyaluronan-high metastatic pancreatic adenocarcinoma. J. Clin. Oncol. 38, 3185\u20133194 (2020).","journal-title":"J. Clin. Oncol."},{"key":"4283_CR10","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1007\/s40265-020-01304-0","volume":"80","author":"RR Singh","year":"2020","unstructured":"Singh, R. R. & O\u2019Reilly, E. M. New treatment strategies for metastatic pancreatic ductal adenocarcinoma. Drugs 80, 647\u2013669 (2020).","journal-title":"Drugs"},{"key":"4283_CR11","doi-asserted-by":"publisher","first-page":"4814","DOI":"10.1158\/1078-0432.CCR-20-0099","volume":"26","author":"ZA Wainberg","year":"2020","unstructured":"Wainberg, Z. A. et al. Open-label, phase I study of nivolumab combined with nab-paclitaxel plus gemcitabine in advanced pancreatic cancer. Clin. Cancer Res. 26, 4814\u20134822 (2020).","journal-title":"Clin. Cancer Res."},{"key":"4283_CR12","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1038\/s41591-022-01829-9","volume":"28","author":"LJ Padr\u00f3n","year":"2022","unstructured":"Padr\u00f3n, L. J. et al. Sotigalimab and\/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial. Nat. Med. 28, 1167\u20131177 (2022).","journal-title":"Nat. Med."},{"key":"4283_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-32591-8","volume":"13","author":"DJ Renouf","year":"2022","unstructured":"Renouf, D. J. et al. The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial therapy in metastatic pancreatic ductal adenocarcinoma. Nat. Commun. 13, 5020 (2022).","journal-title":"Nat. Commun."},{"key":"4283_CR14","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.3390\/cells9112496","volume":"9","author":"V Vultaggio-Poma","year":"2020","unstructured":"Vultaggio-Poma, V., Sarti, A. C. & Di Virgilio, F. Extracellular ATP: a feasible target for cancer therapy. Cells 9, 2496 (2020).","journal-title":"Cells"},{"key":"4283_CR15","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.1016\/S0002-9440(10)61151-0","volume":"160","author":"MC Montesinos","year":"2002","unstructured":"Montesinos, M. C. et al. Adenosine promotes wound healing and mediates angiogenesis in response to tissue injury via occupancy of A(2A) receptors. Am. J. Pathol. 160, 2009\u20132018 (2002).","journal-title":"Am. J. Pathol."},{"key":"4283_CR16","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1038\/414916a","volume":"414","author":"A Ohta","year":"2001","unstructured":"Ohta, A. & Sitkovsky, M. Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage. Nature 414, 916\u2013920 (2001).","journal-title":"Nature"},{"key":"4283_CR17","doi-asserted-by":"publisher","first-page":"3723","DOI":"10.4161\/cc.8.22.10026","volume":"8","author":"I Martins","year":"2009","unstructured":"Martins, I. et al. Chemotherapy induces ATP release from tumor cells. Cell Cycle 8, 3723\u20133728 (2009).","journal-title":"Cell Cycle"},{"key":"4283_CR18","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1124\/pharmrev.121.000528","volume":"74","author":"GG Yegutkin","year":"2022","unstructured":"Yegutkin, G. G. & Boison, D. ATP and adenosine metabolism in cancer: exploitation for therapeutic gain. Pharmacol. Rev. 74, 797\u2013822 (2022).","journal-title":"Pharmacol. Rev."},{"key":"4283_CR19","doi-asserted-by":"publisher","first-page":"13132","DOI":"10.1073\/pnas.0605251103","volume":"103","author":"A Ohta","year":"2006","unstructured":"Ohta, A. et al. A(2A) adenosine receptor protects tumors from antitumor T cells. Proc. Natl. Acad. Sci. USA 103, 13132\u201313137 (2006).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"4283_CR20","doi-asserted-by":"publisher","first-page":"TPS788","DOI":"10.1200\/JCO.2020.38.4_suppl.TPS788","volume":"38","author":"JC Bendell","year":"2020","unstructured":"Bendell, J. C. et al. A phase I study to evaluate the safety and tolerability of AB680 combination therapy in participants with gastrointestinal malignancies. J. Clin. Oncol. 38, TPS788 (2020).","journal-title":"J. Clin. Oncol."},{"key":"4283_CR21","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1158\/1535-7163.MCT-21-0802","volume":"21","author":"D Piovesan","year":"2022","unstructured":"Piovesan, D. et al. Targeting CD73 with AB680 (quemliclustat), a novel and potent small-molecule CD73 inhibitor, restores immune functionality and facilitates antitumor immunity. Mol. Cancer Ther. 21, 948\u2013959 (2022).","journal-title":"Mol. Cancer Ther."},{"key":"4283_CR22","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1158\/2159-8290.CD-19-0980","volume":"10","author":"L Fong","year":"2020","unstructured":"Fong, L. et al. Adenosine 2A receptor blockade as an immunotherapy for treatment-refractory renal cell cancer. Cancer Discov. 10, 40\u201353 (2020).","journal-title":"Cancer Discov."},{"key":"4283_CR23","doi-asserted-by":"publisher","first-page":"2176","DOI":"10.1158\/1078-0432.CCR-19-2183","volume":"26","author":"B Sidders","year":"2020","unstructured":"Sidders, B. et al. Adenosine signaling is prognostic for cancer outcome and has predictive utility for immunotherapeutic response. Clin. Cancer Res. 26, 2176\u20132187 (2020).","journal-title":"Clin. Cancer Res."},{"key":"4283_CR24","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/s41571-020-0382-2","volume":"17","author":"B Allard","year":"2020","unstructured":"Allard, B., Allard, D., Buisseret, L. & Stagg, J. The adenosine pathway in immuno-oncology. Nat. Rev. Clin. Oncol. 17, 611\u2013629 (2020).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"4283_CR25","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s00428-020-02888-4","volume":"478","author":"K Tahkola","year":"2021","unstructured":"Tahkola, K. et al. Prognostic impact of CD73 expression and its relationship to PD-L1 in patients with radically treated pancreatic cancer. Virchows Arch. 478, 209\u2013217 (2021).","journal-title":"Virchows Arch."},{"key":"4283_CR26","doi-asserted-by":"publisher","first-page":"4980","DOI":"10.1158\/1538-7445.AM2019-4980","volume":"79","author":"AR Udyavar","year":"2019","unstructured":"Udyavar, A. R. et al. Altered pan-Ras pathway and activating mutations in EGFR result in elevated CD73 in multiple cancers. Cancer Res. 79, 4980 (2019).","journal-title":"Cancer Res."},{"key":"4283_CR27","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1053\/j.seminoncol.2021.02.003","volume":"48","author":"J Luo","year":"2021","unstructured":"Luo, J. KRAS mutation in pancreatic cancer. Semin. Oncol. 48, 10\u201318 (2021).","journal-title":"Semin. Oncol."},{"key":"4283_CR28","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.2174\/187152012803529619","volume":"12","author":"AJ Deutsch","year":"2012","unstructured":"Deutsch, A. J., Angerer, H., Fuchs, T. E. & Neumeister, P. The nuclear orphan receptors NR4A as therapeutic target in cancer therapy. Anticancer Agents Med. Chem. 12, 1001\u20131014 (2012).","journal-title":"Anticancer Agents Med. Chem."},{"key":"4283_CR29","doi-asserted-by":"publisher","first-page":"2274","DOI":"10.3390\/cancers12082274","volume":"12","author":"D Saka","year":"2020","unstructured":"Saka, D. et al. Mechanisms of T-cell exhaustion in pancreatic cancer. Cancers (Basel) 12, 2274 (2020).","journal-title":"Cancers (Basel)"},{"key":"4283_CR30","doi-asserted-by":"publisher","first-page":"12410","DOI":"10.1073\/pnas.1905675116","volume":"116","author":"H Seo","year":"2019","unstructured":"Seo, H. et al. TOX and TOX2 transcription factors cooperate with NR4A transcription factors to impose CD8+ T cell exhaustion. Proc. Natl. Acad. Sci. USA 116, 12410\u201312415 (2019).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"4283_CR31","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1038\/s41588-022-01134-8","volume":"54","author":"WL Hwang","year":"2022","unstructured":"Hwang, W. L. et al. Single-nucleus and spatial transcriptome profiling of pancreatic cancer identifies multicellular dynamics associated with neoadjuvant treatment. Nat. Genet. 54, 1178\u20131191 (2022).","journal-title":"Nat. Genet."},{"key":"4283_CR32","doi-asserted-by":"publisher","first-page":"E1239","DOI":"10.1073\/pnas.1718197115","volume":"115","author":"D Samanta","year":"2018","unstructured":"Samanta, D. et al. Chemotherapy induces enrichment of CD47+\/CD73+\/PDL1+ immune evasive triple-negative breast cancer cells. Proc. Natl. Acad. Sci. USA 115, E1239\u2013E1248 (2018).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"4283_CR33","doi-asserted-by":"publisher","first-page":"6325","DOI":"10.1038\/s41598-020-62968-y","volume":"10","author":"H Maruoka","year":"2020","unstructured":"Maruoka, H. et al. Molecular mechanism of nur77 gene expression and downstream target genes in the early stage of forskolin-induced differentiation in PC12 cells. Sci. Rep. 10, 6325 (2020).","journal-title":"Sci. Rep."},{"key":"4283_CR34","doi-asserted-by":"publisher","first-page":"4459","DOI":"10.1073\/pnas.0501076102","volume":"102","author":"X Zhang","year":"2005","unstructured":"Zhang, X. et al. Genome-wide analysis of cAMP-response element binding protein occupancy, phosphorylation, and target gene activation in human tissues. Proc. Natl. Acad. Sci. USA 102, 4459\u20134464 (2005).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"4283_CR35","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1158\/2159-8290.CD-20-1228","volume":"11","author":"MP Kim","year":"2021","unstructured":"Kim, M. P. et al. Oncogenic KRAS recruits an expansive transcriptional network through mutant p53 to drive pancreatic cancer metastasis. Cancer Discov. 11, 2094\u20132111 (2021).","journal-title":"Cancer Discov."},{"key":"4283_CR36","doi-asserted-by":"publisher","first-page":"11423","DOI":"10.1021\/acs.jmedchem.9b01207","volume":"62","author":"F Xie","year":"2019","unstructured":"Xie, F., Fan, Q., Li, B. X. & Xiao, X. Discovery of a synergistic inhibitor of cAMP-response element binding protein (CREB)-mediated gene transcription with 666-15. J. Med. Chem. 62, 11423\u201311429 (2019).","journal-title":"J. Med. Chem."},{"key":"4283_CR37","doi-asserted-by":"publisher","first-page":"CT212","DOI":"10.1158\/1538-7445.AM2024-CT212","volume":"84","author":"K-P Kim","year":"2024","unstructured":"Kim, K.-P. et al. Phase Ib\/II, global, open-label, randomized evaluation of atezolizumab (atezo) + etrumadenant (etruma) + chemotherapy (chemo) vs chemo alone in MORPHEUS-PDAC. Cancer Res. 84, CT212 (2024).","journal-title":"Cancer Res."},{"key":"4283_CR38","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1093\/bjs\/znac272","volume":"109","author":"JA Suurmeijer","year":"2022","unstructured":"Suurmeijer, J. A. et al. Impact of classical and basal-like molecular subtypes on overall survival in resected pancreatic cancer in the SPACIOUS-2 multicentre study. Br. J. Surg. 109, 1150\u20131155 (2022).","journal-title":"Br. J. Surg."},{"key":"4283_CR39","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1158\/1078-0432.CCR-18-1316","volume":"25","author":"M Ayers","year":"2019","unstructured":"Ayers, M. et al. Molecular profiling of cohorts of tumor samples to guide clinical development of pembrolizumab as monotherapy. Clin. Cancer Res. 25, 1564\u20131573 (2019).","journal-title":"Clin. Cancer Res."},{"key":"4283_CR40","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/j.ccell.2021.04.014","volume":"39","author":"A Bagaev","year":"2021","unstructured":"Bagaev, A. et al. Conserved pan-cancer microenvironment subtypes predict response to immunotherapy. Cancer Cell 39, 845\u2013865 (2021).","journal-title":"Cancer Cell"},{"key":"4283_CR41","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.ccell.2020.11.015","volume":"39","author":"CS Grasso","year":"2021","unstructured":"Grasso, C. S. et al. Conserved interferon-\u03b3 signaling drives clinical response to immune checkpoint blockade therapy in melanoma. Cancer Cell 39, 122 (2021).","journal-title":"Cancer Cell"},{"key":"4283_CR42","doi-asserted-by":"publisher","first-page":"C007","DOI":"10.1158\/1538-7445.PANCREATIC24-C007","volume":"84","author":"JY Kim","year":"2024","unstructured":"Kim, J. Y. et al. Quemliclustat (CD73 inhibitor) reduces adenosine-regulated NR4A gene expression and increases mPDAC inflammation in patients from the ARC-8 trial. Cancer Res. 84, C007 (2024).","journal-title":"Cancer Res."},{"key":"4283_CR43","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","volume":"369","author":"DD Von Hoff","year":"2013","unstructured":"Von Hoff, D. D. et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N. Engl. J. Med. 369, 1691\u20131703 (2013).","journal-title":"N. Engl. J. Med."},{"key":"4283_CR44","doi-asserted-by":"publisher","first-page":"S147\u2212S148","DOI":"10.1016\/j.annonc.2025.05.399","volume":"36","author":"TM Mercade","year":"2025","unstructured":"Mercade, T. M. et al. Quemliclustat and chemotherapy in previously untreated patients with metastatic pancreatic ductal adenocarcinoma: PRISM-1, a randomized, placebo-controlled, phase III trial. Ann. Oncol. 36, S147\u2212S148 (2025).","journal-title":"Ann. Oncol."},{"key":"4283_CR45","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1200\/jco.2014.32.3_suppl.178","volume":"32","author":"D Goldstein","year":"2014","unstructured":"Goldstein, D. et al. Updated survival from a randomized phase III trial (MPACT) of nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients (pts) with metastatic adenocarcinoma of the pancreas. J. Clin. Oncol. 32, 178 (2014).","journal-title":"J. Clin. Oncol."},{"key":"4283_CR46","doi-asserted-by":"publisher","first-page":"4609","DOI":"10.1158\/1078-0432.CCR-24-0499","volume":"30","author":"AL Coveler","year":"2024","unstructured":"Coveler, A. L. et al. A phase Ib\/II randomized clinical trial of oleclumab with or without durvalumab plus chemotherapy in patients with metastatic pancreatic ductal adenocarcinoma. Clin. Cancer Res. 30, 4609\u20134617 (2024).","journal-title":"Clin. Cancer Res."},{"key":"4283_CR47","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. US Department of Health and Human Services. https:\/\/dctd.cancer.gov\/research\/ctep-trials\/for-sites\/adverse-events\/ctcae-v5-5x7.pdf (2017)."},{"key":"4283_CR48","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228\u2013247 (2009).","journal-title":"Eur. J. Cancer"},{"key":"4283_CR49","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1093\/aje\/kwq224","volume":"172","author":"PC Austin","year":"2010","unstructured":"Austin, P. C. Statistical criteria for selecting the optimal number of untreated subjects matched to each treated subject when using many-to-one matching on the propensity score. Am. J. Epidemiol. 172, 1092\u20131097 (2010).","journal-title":"Am. J. Epidemiol."},{"key":"4283_CR50","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1002\/pst.433","volume":"10","author":"PC Austin","year":"2011","unstructured":"Austin, P. C. Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies. Pharm. Stat. 10, 150\u2013161 (2011).","journal-title":"Pharm. Stat."},{"key":"4283_CR51","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1080\/03610910902859574","volume":"38","author":"PC Austin","year":"2009","unstructured":"Austin, P. C. Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research. Commun. Stat. Simul. Comput. 38, 1228\u20131234 (2009).","journal-title":"Commun. Stat. Simul. Comput."},{"key":"4283_CR52","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/00273171.2011.568786","volume":"46","author":"PC Austin","year":"2011","unstructured":"Austin, P. C. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav. Res. 46, 399\u2013424 (2011).","journal-title":"Multivariate Behav. Res."},{"key":"4283_CR53","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/S0895-4356(00)00321-8","volume":"54","author":"S-LT Normand","year":"2001","unstructured":"Normand, S.-L. T. et al. Validating recommendations for coronary angiography following acute myocardial infarction in the elderly: a matched analysis using propensity scores. J. Clin. Epidemiol. 54, 387\u2013398 (2001).","journal-title":"J. Clin. Epidemiol."},{"key":"4283_CR54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1214\/09-STS313","volume":"25","author":"EA Stuart","year":"2010","unstructured":"Stuart, E. A. Matching methods for causal inference: a review and a look forward. Stat. Sci. 25, 1\u201321 (2010).","journal-title":"Stat. Sci."},{"key":"4283_CR55","unstructured":"FastQC. https:\/\/qubeshub.org\/resources\/fastqc (2015)."},{"key":"4283_CR56","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15\u201321 (2013).","journal-title":"Bioinformatics"},{"key":"4283_CR57","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/nmeth.4197","volume":"14","author":"R Patro","year":"2017","unstructured":"Patro, R., Duggal, G., Love, M. I., Irizarry, R. A. & Kingsford, C. Salmon provides fast and bias-aware quantification of transcript expression. Nat. Methods 14, 417\u2013419 (2017).","journal-title":"Nat. Methods"},{"key":"4283_CR58","doi-asserted-by":"publisher","first-page":"D766","DOI":"10.1093\/nar\/gky955","volume":"47","author":"A Frankish","year":"2019","unstructured":"Frankish, A. et al. GENCODE reference annotation for the human and mouse genomes. Nucleic Acids Res. 47, D766\u2013D773 (2019).","journal-title":"Nucleic Acids Res."},{"key":"4283_CR59","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2014-15-2-r29","volume":"15","author":"CW Law","year":"2014","unstructured":"Law, C. W., Chen, Y., Shi, W. & Smyth, G. K. voom: precision weights unlock linear model analysis tools for RNA-seq read counts. Genome Biol. 15, R29 (2014).","journal-title":"Genome Biol."},{"key":"4283_CR60","doi-asserted-by":"publisher","unstructured":"Korotkevich, G., Sukhov, V., Budin N., Shpak B., Artyomov M. N. & Sergushichev, A. Fast gene setenrichment analysis. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/060012 (2021).","DOI":"10.1101\/060012"},{"key":"4283_CR61","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/nature08460","volume":"462","author":"DA Barbie","year":"2009","unstructured":"Barbie, D. A. et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 462, 108\u2013112 (2009).","journal-title":"Nature"},{"key":"4283_CR62","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1471-2105-14-7","volume":"14","author":"S H\u00e4nzelmann","year":"2013","unstructured":"H\u00e4nzelmann, S., Castelo, R. & Guinney, J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics 14, 7 (2013).","journal-title":"BMC Bioinformatics"},{"key":"4283_CR63","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1038\/nmeth.4463","volume":"14","author":"S Aibar","year":"2017","unstructured":"Aibar, S. et al. SCENIC: single-cell regulatory network inference and clustering. Nat. Methods 14, 1083\u20131086 (2017).","journal-title":"Nat. Methods"},{"key":"4283_CR64","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1158\/1078-0432.CCR-19-1467","volume":"26","author":"NU Rashid","year":"2020","unstructured":"Rashid, N. U. et al. Purity Independent Subtyping of Tumors (PurIST), a clinically robust, single-sample classifier for tumor subtyping in pancreatic cancer. Clin. Cancer Res. 26, 82\u201392 (2020).","journal-title":"Clin. Cancer Res."},{"key":"4283_CR65","unstructured":"survminer: drawing survival curves using \u2018ggplot2\u02bc. https:\/\/cloud.r-project.org\/web\/packages\/survminer\/index.html (2025)."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04283-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04283-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04283-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T14:02:33Z","timestamp":1776780153000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04283-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,30]]},"references-count":65,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["4283"],"URL":"https:\/\/doi.org\/10.1038\/s41591-026-04283-z","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,30]]},"assertion":[{"value":"31 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Z.A.W. has served as a consultant for AbbVie, Alligator, Amgen, Arcus Biosciences, AstraZeneca, Bayer, BeOne, Bristol Myers Squibb, Daiichi-Sankyo, Ipsen, Jannsen, Jazz Pharmaceuticals, Lilly, Merck, Merck KGaA, Novartis, Phanes, Pfizer and Revolution Medicines; received institutional research funding from Arcus Biosciences, Merck, Novartis and Plexxikon; and has been reimbursed for travel, accommodations or other expenses by Amgen, Lilly and Merck. G.A.M. reports consulting or advisory roles with Cend Therapeutics, EnGeneic, Exelixis, Ipsen and Roche\/Genentech; reports travel\/accommodation\/expenses from Celgene, Exelixis and Roche\/Genentech; reports honoraria from Celgene, Cend Therapeutics, Exelixis and Roche\/Genentech; and reports research funding from Arcus Biosciences, BioLineRx, Merck, Plexxikon, Regeneron and Roche\/Genentech. N.B. reports consulting or advisory roles with Amgen, AstraZeneca, Bristol Myers Squibb, Incyte, Pfizer and Taiho. S.V.U. reports consulting or advisory roles with AstraZeneca, Eisai, IgM Biosciences and reports research funding from AbbVie, Adlai Nortye, ArQule, Astex Pharmaceuticals, AstraZeneca, Atreca, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, CicloMed, Erasca, Evelo Biosciences, Exelixis, G1 Therapeutics, GlaxoSmithKline, IgM Biosciences, Incyte, KLUS Pharma, MacroGenics, Merck, Mersana, NGM Biopharmaceuticals, OncoMed, Pfizer, Pionyr, Regeneron, Revolution Medicines, Synermore Biologics, Takeda, Tarveda Therapeutics, Tempest Therapeutics, TESARO and Vigeo Therapeutics. S.P. reports consulting or advisory roles with AskGene Pharma, Boehringer Ingelheim, Ipsen, Janssen, Novartis and Zymeworks and reports research funding from 4D Pharma, AMAL Therapeutics, Arcus Biosciences, Astellas Pharma, BioNTech, Boehringer Ingelheim, Bristol Myers Squibb, Elicio Therapeutics, Immuneering, ImmunoMet, Ipsen, Janssen, Lilly, Mirati Therapeutics, NGM Biopharmaceuticals, Novartis, Pfizer, Purple Biotech, Rgenix, Xencor and Zymeworks. D.R.S. reports research funding (paid to the institution) from AbbVie, Agios, Amgen, AnHeart Therapeutics, Apollomics, Arcus Biosciences, Arrys Therapeutics, Ascendis Pharma, Asher Biotherapeutics, Astellas Pharma, AstraZeneca, Bayer, BeiGene, BioNTech RNA Pharmaceuticals, Blueprint Medicine, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Chugai, Cyteir Therapeutics, Daiichi-Sankyo, Denovo Biopharma, Eisai, Elevation Oncology, Ellipses Pharma, EMD Serono, Endeavor, Erasca, Faeth Therapeutics, Foundation Bio, Fujifilm Pharmaceuticals, G1 Therapeutics, Roche\/Genentech, Gilead Sciences, GlaxoSmithKline, GRAIL, Hutchison MediPharma, Incyte, Ipsen, Janssen, Janux Therapeutics, Jazz Pharmaceuticals, Kronos Bio, Lilly, Loxo Oncology, Lyell Immunopharma, MacroGenics, MedImmune, Merck, Millennium Pharmaceuticals, Moderna, Molecular Template, Monte Rosa Therapeutics, Nektar, Novartis, Novocure, Oncologie, Peloton Therapeutics, Phanes Therapeutics, PTC Therapeutics, PureTech Health, Razor Genomics, Repare Therapeutics, Rgenix, SeaGen, Shenzhen Chipscreen Biosciences, Strata Oncology, Stemline Therapeutics, Synthekine, Taiho, Takeda Pharmaceuticals, Tango Therapeutics, Tarveda, Tizona Therapeutics, Verastem and Zai Laboratory and reports consulting or advisory roles (paid to the institution) with AbbVie, Amgen, AstraZeneca, Circle Pharma, Daiichi Sankyo, GlaxoSmithKline, Jazz Pharmaceuticals, Lyell, MedImmune, ModeX Therapeutics, Novartis, Novocure and Roche\/Genentech. N.V.U. reports consulting or advisory roles with Arcus Biosciences, Astellas Pharma, AstraZeneca, BeiGene, BostonGene, Bristol Myers Squibb Foundation, Bristol Myers Squibb\/Roche, Eisai\/MSD, Elevation Oncology, Gilead Sciences, Ipsen, Merck and Pfizer; reports stock and other ownership interests with Exact Sciences and Natera; and reports research funding from Arcus Biosciences, EMD Serono, Gilead Sciences and Ipsen. P.E.O. reports consulting or advisory roles with Amal Therapeutics, Aravive, AstraZeneca, Merck, QED Therapeutics and Rubius Therapeutics; reports speakers bureau with AstraZeneca; reports travel\/accommodations\/expenses from Merck; reports expert testimony for Ipsen; and reports research funding from Amal Therapeutics, Arcus Biosciences, Cornerstone Pharmaceuticals, Merck, Novartis, Roche\/Genentech and Zai Laboratory. A.S. reports research grants to the institution from Actuate Therapeutics, Arcus Biosciences, AstraZeneca, Bristol Myers Squibb, Clovis, Exelixis, Incyte Corporation, Daiichi-Sankyo, Dragonfly Therapeutics, Five Prime Therapeutics, Amgen, Innovent Biologics, KAHR Medical, Merck and Oxford Biotherapeutics and reports advisory board\/consulting fees from Amgen, Arcus Biosciences, AstraZeneca, Autem Therapeutics, Bristol Myers Squibb, Daiichi-Sankyo, Exelixis, KAHR Medical, Merck, Pfizer, Xilio Therapeutics and Taiho. B.B. was an employee of Arcus Biosciences when this study was conducted and may own Arcus Biosciences stock and\/or stock options. J.Y.K., N.W., B.W., S.S., K.M., J.R.S., D.M.D., M.J.W., W.W., A.K., S.C. and O.K. are employees of Arcus Biosciences and may own stock and\/or stock options. L.G.E. is an employee of Medidata Solutions Inc., a Dassault Syst\u00e8mes company, and may own stock and\/or stock options. E.M.O. has received institutional research funding from Agenus, Amgen, Arcus Biosciences, AstraZeneca, BioNTech, Break Through Cancer, Digestive Care, Elicio, Genentech\/Roche, the National Institutes of Health\/National Cancer Institute (NIH\/NCI), the Parker Institute and Revolution Medicines; served (uncompensated) as a consultant or on a data safety monitoring board for Ability Pharma, Agenus, Alligator Bioscience, Amgen, Arcus Biosciences, Astellas Pharma, AstraZeneca, BioNTech, Bristol Myers Squibb, Ikena, Ispen, Merck, Moma Therapeutics, Novartis, Regeneron, Revolution Medicines and Tango; served (compensated) as a consultant or on a data safety monitoring board for Leap Therapeutics; received travel funding from Arcus Biosciences and BioNTech; and declares other potential competing interests including a spouse (AbbVie and AstraZeneca) and association with the American Association of Cancer Research, the American Society of Clinical Oncology, Imedex, Research To Practice, Stand Up To Cancer and the NIH\/NCI. She has received grant funding from the Cancer Center Support Grant\/Core (grant P30 CA008748) and the NCI\/NIH (P50 CA257881-01A1).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}